JLJoão Victor Antunes Lopes

João Victor Antunes Lopes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


João Victor Antunes Lopes has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction to: COVID-19, Excess Deaths, and Mortality: Evidence from a Municipality in Brazil

    by Antunes Lopes, João Victor, Luciana Correia Alves, de Moraes, Rafael Rodrigues

  • COVID-19, Excess Deaths, and Mortality: Evidence from a Municipality in Brazil

    by Antunes Lopes, João Victor, Luciana Correia Alves, Rafael Rodrigues de Moares


  • Open Access

    Estimating depression-free life expectancy in the hearing-impaired population in Brazil

    by Rafael Rodrigues de Moraes, João Victor Antunes Lopes, Luciana Correia Alves

    Individuals with hearing impairments are more vulnerable to depression. According to the 2010 Brazilian Demographic Census, around 10 million people have some degree of hearing impairment. Brazil also ranks highest in depression among middle-income countries. The prevalence of mental health conditions in the Brazilian hearing-impaired population remains an understudied topic. This study aims to quantify the impact of depression on the life expectancy of the Brazilian population with hearing impairment. We used data from the 2019 edition of the National Health Survey and from the 2010 Brazilian Institute of Geography and Statistics (Instituto Brasileiro de Geografia e Estatística, IBGE) Census to apply the Sullivan method (1971). Our results show that young women with severe hearing impairment are the population group that requires special attention due to the strong effect of depression on life expectancy. It is also possible that men have an underestimated prevalence of depression, which may obscure their years lived without depression. Targeted public policies are recommended to reduce communication barriers between patients, physicians, and other health professionals by promoting fluency in Brazilian Sign Language and knowledge of Deaf culture and their specific needs.


  • Open Access

    Clinical trials of COVID-19 vaccine development: a global overview

    by João Victor Antunes Lopes, André Luiz Sica de Campos, Rafael Rodrigues de Moraes, Luciana Correia Alves

    This study aims to report analyses regarding the global distribution of institutions involved in clinical trials of COVID-19 vaccines throughout February 2022. We retrieved global data from the World Health Organization report on vaccine development. These data allowed us to identify project institutions and plot their geographic coordinates. We produced a georeferenced map using an R programming environment and, based on the geographical location of vaccine developers, we analyzed the subcontinental distribution of clinical trials and the nature of the vaccines. Regionally, South-Southeast Asian countries carried out more clinical trials than any other region, proportionally, although this happened solely for mature technologies. Few trials were under implementation in Latin America and Africa. Our findings confirm previous studies on the regional concentration in the development of technology. However, our contribution lies in showing these phenomena for COVID-19 vaccines in specific subcontinents and technologies, at a country level. Our data underscores which subcontinents perform very few clinical trials for COVID-19 and seem to be ill-prepared for future disease outbreaks, and if these become epidemics or even pandemics and require domestic vaccine development or production. We also consider the case of Brazil, which did not finish the complete cycle of COVID-19 vaccine development in the indicated period; but, with favorable policies, it has potential to engage further in COVID-19 vaccine technology.